Pfizer Shot Remains More Than 91% Effective After Six Months


·         Pfizer, BioNTech release follow-up data from phase 3 trial

·         Covid vaccination stopped almost all cases of severe illness


By Robert Langreth, Bloomberg 

April 1, 2021


The Pfizer Inc.-BioNTech SE vaccine remained highly effective against Covid-19 after six months, according to new long-term results that Pfizer said could be used to seek an expansion of the shot’s regulatory status.


Follow-up data from a final-stage trial of 46,307 people showed the vaccine was 91.3% effective in preventing symptomatic cases starting one week after the second dose through as long as six months. In the U.S. alone, the efficacy rate was 92.6%, according to a report Thursday by the two companies.


At the same time, the companies provided some of the first data on how their vaccine might handle the immune-evading B.1.351 variant that arose in South Africa. Nine of 800 trial participants in that country got sick with Covid, including six infected with B.1.351. However, all were in the placebo group, suggesting the shot retains efficacy against the variant.


Albert Bourla, Pfizer’s Chief Executive Officer, said in the statement that the results “position us to submit a Biologics License Application to the U.S. FDA.”


more, including links